Table 1.

Tumors responsive toward ATF5 antagonism.

Tumor Type	Tumor origin	d/n-ATF5 Antagonism Method	Outcomes
Glioma	In vitro	Transgene transfection [1]	Apoptosis[1]
	In vivo
	Allograft	Retrovirus [1]	Apoptosis [1]
	Induced Gliomas	Transgenic [11]	Prevention/Eradication [11]
	Orthotopic	CP-d/n-ATF5-RP [12]	Growth Attenuation [12]
	Orthotopic	CP-d/n-ATF5-S1 [5]	Growth Attenuation [5]
	Xenograft	CP-d/n-ATF5-S1 [5]	Growth Attenuation [5]
Epithelial Ovarian	In vitro	Transgene transfection [9]	Apoptosis [9]
Breast	In vitro	Transgene transfection [1]	Apoptosis [1]
	In vivo
	Orthotopic	CP-d/n-ATF5-S1 [5]	Regression [5]
Pancreatic	In vitro	Transgene transfection [10]	Apoptosis [10]
	In vivo
	Xenograft	CP-d/n-ATF5-S1 [5, 10]	No Growth Attenuation [5]
Prostate (hormone-refractory)	In vitro	CP-d/n-ATF5-S1 [5]	Apoptosis [5]
	In Vivo
	Xenograft	CP-d/n-ATF5-S1 [5]	Growth Attenuation [5]
Lung (non-small cell)	In vitro	CP-d/n-ATF5-S1 [5]	Apoptosis [5]
Colorectal	In vivo/Xenograft	CP-d/n-ATF5-S1 [5]	No Growth Attenuation [5]
Melanoma (BRAF mutated)	In vitro	CP-d/n-ATF5-S1 [5]	Apoptosis [5]
	In vivo
	Orthotopic	CP-d/n-ATF5-S1 [5]	Growth Attenuation [5]
Myeloid Leukemia	In vitro	CP-d/n-ATF5-S1 [5]	Apoptosis [5]
B-Cell Lymphoma	In vitro	CP-d/n-ATF5-S1 [5]	Apoptosis [5]
Chronic Myeloid Leukemia	In vitro	CP-d/n-ATF5-S1 [5]	Apoptosis [5]
Raji Burkitt Lymphoma Cells	In vitro	CP-d/n-ATF5-S1 [5]	Apoptosis [5]